Long-acting and Extended‑Release Opioid Agents — Coverage Criteria
Customize your policy alerts
Sign up for Blue Cross Blue Shield - Iowa Policy 05.02.35 alerts
Get alerted when Policy 05.02.35 changes without checking for updates manually.
Monitor payer policy activity
Defines indications and limitations of use for specific long-acting/extended-release opioid medications and describes benefit application for Wellmark members; intended for providers making coverage requests and prescribing these agents.
No material clinical or coverage changes in this revision.
Coverage Criteria for Long‑Acting / Extended‑Release Opioids
Agent-specific coverage criteria (partial list)
Covered when ALL of the following are met
Supported by product indications for multiple named agents
Repeated limitation across product labeling
Explicit limitation in product limitations of use
Coverage criteria for long-acting and selected opioid products
Covered when ALL of the following are met
Supported for each named ER/LA product
Consistent with limitations of use
ER/LA opioids not indicated for PRN use
Methadone regulatory conditions
Additional regulatory coverage constraints for methadone when used for opioid addiction
Failure to comply may have legal and coverage implications
Document program certification status or applicable regulatory exception
Quantity limits and labeling differentiate analgesic use from addiction programs
Coverage with Prior Authorization
Covered when ANY of the indication criteria are met AND all monitoring/safety criteria are met (PA required unless step therapy satisfied):
Routing/exemption for cancer/SCD/palliative care described
Monitoring and reassessment expectations per policy
Step therapy criteria to avoid PA; otherwise PA required
Regulatory and safety restriction for methadone products
Quantity limits and step timeline
Quantity limits are defined per product/strength and accumulate across like unit limits; initial (Column A/B) and post 1/3 month (Column C/D) MME-based caps apply.
Columns A/B = initial limits; Columns C/D = post 1/3 month limits
Examples and blocked strengths ('0***') are detailed in the chart
ER Opioid Quantity Limit Rules
Quantity limits and dosing intervals by product and strength (applies when dispensing ER opioid formulations):
Examples: fentanyl transdermal 25 mcg/hr and multiple hydrocodone/hydromorphone/morphine/methadone entries
Multiple products and strengths show '0***' in chart
This medical policy may not apply to Federal Employee Program (FEP) members. Benefit determinations for FEP are governed by the Federal Employee Program and may differ from the provisions in this policy; verify individual member benefits and contract language at the time of service to determine applicable coverage rules.
Use of the listed long‑acting and extended‑release opioid products for as‑needed (prn) analgesia is not an indicated use and is excluded. These formulations are reserved for patients requiring scheduled, daily, around‑the‑clock opioid therapy when alternative options are ineffective, not tolerated, or inadequate, consistent with product labeling and the policy’s clinical rationale.
Xtampza ER is not indicated as an as‑needed (prn) analgesic. Per product labeling and the policy rationale, Xtampza ER should be reserved for patients whose pain requires daily, around‑the‑clock, long‑term opioid treatment and for whom nonopioid or immediate‑release opioid alternatives are ineffective, not tolerated, or inadequate.
Certain product/strength entries in the Opioid Analgesics ER Quantity Limits Chart are shown as "0***". Strengths or supply levels marked with "0***" are effectively excluded from standard dispensing at that supply level under the policy and are subject to denial or require a prior authorization/exception to be dispensed.
Patients with claims or diagnosis codes indicating cancer, sickle cell disease, palliative care, or hospice within the specified look‑back periods are routed to the prescription benefit and are exempt from the step‑therapy and post‑limit quantity restrictions described in this policy. Evidence of such diagnoses or relevant prescription claims in the past 365 days will cause the request to be paid under the prescription benefit pathway rather than under the ER/LA opioid step‑therapy logic.
Long‑acting/extended‑release opioid formulations are intended for scheduled, around‑the‑clock use and are not indicated for as‑needed (PRN) analgesia. Prescribing any of the listed ER/LA opioid products as PRN use would be inconsistent with labeling, the clinical rationale, and the policy and therefore would not meet coverage criteria.
Initiation of long‑acting/extended‑release opioid formulations should be reserved for patients for whom alternative treatments (nonopioid analgesics or immediate‑release opioid options) have been tried and found ineffective, not tolerated, or otherwise inadequate. Per the policy, prescribers are expected to document prior conservative therapy and to follow step‑therapy expectations before initiating ER/LA opioids; absence of such documentation may trigger claim rejection or prior authorization requirements.
Initiation of an ER opioid without a prior trial of an immediate‑release (IR) opioid (at least a 8‑day supply within the past 90 days) or without evidence that the patient has been stable on an ER opioid (at least a 30‑day supply within the past 90 days) will result in claim rejection and require prior authorization. These step‑therapy requirements are used to confirm prior opioid exposure before approving ER initiation under standard quantity limits.
ER/LA opioids are not indicated for intermittent (PRN) use or for initiation in acute pain. The policy follows CDC and guideline recommendations that ER/LA opioids be reserved for severe, continuous pain and only after appropriate trials of alternative therapy; initiation of ER/LA opioids for subacute or chronic pain without prior appropriate IR exposure is contrary to guidance and will require prior authorization or be denied.
Initial coverage and PA criteria
Covered when ALL of the following are met
Routing and exemptions described in clinical rationale
If not met, claim rejects and PA is required
Requests above initial limits will require prior authorization; post‑limits up to ~200 MME/day can be considered with PA
Consistent with CDC guidance and product labeling
Continuation and dose limits
Continuation / post‑authorization considerations
Approval duration based on clinical rationale and evidence limitations
Policy sets post‑limit cap to ~200 MME/day unless FDA‑labeled dosing exceeds this
Conservative Treatment and Step Therapy Expectations
Conservative therapy — general limitation of use
Provider-action: Prior authorization and step therapy expectations for long-acting / extended-release (ER) opioid agents.
Screenout to disease‑specific benefit
Provider-action: Screenout to disease-specific prescription benefit (no PA under medical/drug benefit) — claims or member profile indicating cancer, sickle cell disease, palliative care, or hospice.
Initial step therapy — IR trial or ER stability required
Provider-action: Initial Step Therapy requirements for patients without disease-specific indicators (cancer, SCD, palliative care, hospice).
ALL of the following
- IR opioid exposure: The patient has filled at least an 8‑day supply of an immediate‑release (IR) opioid agent indicated for management of pain within the past 90 days under the prescription benefit administered by CVS Caremark.
- ER opioid stability: The patient has filled at least a 30‑day supply of an extended‑release (ER) opioid agent indicated for management of pain within the past 90 days under the prescription benefit administered by CVS Caremark (patient stable on ER opioid).
Prior authorization required if step not met
Provider-action: Prior authorization required when initial step therapy not met.
Step therapy exceptions and operational notes
Provider-action: Step therapy exceptions and additional notes.
Provider Actions, Prior Authorization & Documentation
Prior authorization and documentation — verify benefits and contract exclusions
Verify individual member benefits and contract exclusions/limitations at the time of service; Wellmark determines medical necessity only if the benefit exists and no contract exclusions apply.
- Benefit verification is required because coverage may vary by contract and some members (e.g., FEP) are excluded from this medical policy.
Prior authorization for long‑acting opioids — confirm alternatives and intent for chronic around‑the‑clock use
Prior authorization is recommended or required when prescribing long‑acting or extended‑release opioid formulations to confirm that alternatives were tried and that therapy is intended for daily, around‑the‑clock long‑term pain management rather than as‑needed use.
- PA ensures documentation that alternatives were ineffective, not tolerated, or inadequate and that safety/monitoring criteria will be met.
PA required when no prior opioid exposure or when requesting quantities above initial MME limits
Prior authorization is required when step therapy conditions are not met (no qualifying prior IR or ER opioid use within the specified look‑back) or when the requested ER opioid quantity exceeds initial limits corresponding to ≤90 MME/day and seeks higher dosing up to the PA‑allowed ≤200 MME/day.
- Claims lacking ≥8‑day IR or ≥30‑day ER fills in the past 90 days will reject and require PA.
- Requests exceeding initial quantity limits (~90 MME/day) will reject and require PA for potential approval up to ≤200 MME/day per policy.
PA for restricted strengths — '0***' strengths require authorization
Certain higher strengths and quantities are designated as '0***' in the quantity limits chart; these restricted strengths/quantities require prior authorization for dispensing outside standard monthly or 3‑month caps.
- Examples in the chart show multiple strengths (e.g., fentanyl patches, higher ER tablet strengths) marked '0***' indicating restriction.
PA for ER opioid initiation or excess quantity — authorize when no qualifying history or quantity exceeds initial limit
Prior authorization is required when the patient lacks qualifying recent opioid prescription history (no ≥8‑day IR or ≥30‑day ER fill in the past 90 days) or when the requested ER quantity exceeds the initial quantity limits corresponding to approximately 90 MME/day.
- When PA is required, the PA unit will apply the prior authorization criteria to evaluate the request.
Prior authorization — unspecified details
Prior authorization details not specified in these source chunks.
Benefit verification and medical necessity — confirm coverage before requesting PA
Verify individual member benefits and contract exclusions/limitations at the time of service; Wellmark determines medical necessity only if the benefit exists and no contract exclusions apply.
- Benefit verification determines whether this medical policy applies to the member (e.g., FEP members are excluded).
Clinical indication documentation — record chronic, around‑the‑clock pain and failed alternatives
Document that the patient has pain severe enough to require daily, around‑the‑clock, long‑term opioid therapy and that alternative analgesic options are ineffective, not tolerated, or inadequate.
- Chronic pain is generally defined as pain lasting greater than 3 months; indicate whether the request is for continuation or initiation.
Methadone regulatory documentation — document OTP certification or exception for addiction treatment
When methadone is prescribed in the context of opioid addiction treatment, document program certification status or applicable regulatory exception (e.g., inpatient care or emergency short‑term use) per 42 CFR 8 and 21 CFR 1306.07.
- Methadone for addiction treatment must be dispensed only by certified Opioid Treatment Programs except in narrow regulatory exceptions; document compliance.
Monitoring and reassessment — document safety assessments and scheduled rechecks
Document that the patient can safely take the requested dose based on opioid history, that evaluation and regular monitoring for opioid use disorder will occur, and that pain and function will be reassessed within one month after initiation or dose increase and every 3 months thereafter.
- Monitoring documentation should reflect planned reassessment intervals and risk evaluation (e.g., substance use history, CNS depressant use, MME exposure).
Indication documentation — record disease‑specific or chronic pain indication
Document the specific indication: cancer, sickle cell disease, terminal condition, hospice/palliative care, or chronic pain severe enough to require daily, around‑the‑clock, long‑term opioid therapy.
- Indication documentation determines routing (prescription benefit vs. this pathway) and applicability of step therapy/post‑limit quantities.
Prescription detail — include strength and quantity for limit verification
Prescriptions should indicate strength and quantity to permit verification against per‑month and per‑3‑month caps and MME equivalence.
- Provide explicit strength and quantity on the prescription/claim to allow system checks against initial and post limits (~90 MME/day and ≤200 MME/day).
Required prescription claim history / diagnosis evidence — supply prior‑use or disease evidence
Provide evidence of prior opioid use in prescription claims history (an ≥8‑day IR opioid fill in the past 90 days or a ≥30‑day ER opioid fill in the past 90 days) or documentation supporting cancer, sickle cell disease, palliative, or hospice status (within past 365 days) to determine routing and apply initial quantity limits.
- Absence of qualifying prior fills will cause claim rejection requiring PA.
- Disease‑specific documentation routes the request to the prescription benefit and exempts step therapy.
Procedure and billing codes — use correct CPT/HCPCS/revenue/ICD codes
Report provider services using appropriate CPT, HCPCS, revenue, and/or ICD diagnostic codes; failure to use appropriate codes may trigger billing denials.
- Accurate coding supports benefit determination and billing; ensure diagnosis codes reflect indication (e.g., cancer, SCD, palliative care) when applicable.
Benefit/contract denial risk — verify member benefits and exclusions
Benefit determinations are based on applicable contract language and exclusions/limitations may apply; services may be denied if benefits are not available under the member's contract or exclusions apply.
- Verify member benefits before prescribing or submitting PA requests; this policy may not apply to Federal Employee Program (FEP) members.
Indication/PRN mismatch risk — PRN use or adequate alternatives may lead to denial
Use of long‑acting/extended‑release opioid products or methadone as as‑needed (PRN) analgesics, or when adequate alternative analgesic options exist, may be inconsistent with limitations of use and can trigger coverage denial.
- ER/LA opioids are explicitly not indicated for PRN use; initiation without documented failure of alternatives risks denial.
Regulatory compliance risk — methadone addiction dispensing must follow 42 CFR 8
Dispensing methadone for opioid addiction outside certified Opioid Treatment Programs (OTPs) may violate 42 CFR 8 and lead to regulatory sanctions and denial of coverage for misuse of distribution channels.
- Document OTP certification or applicable regulatory exception when methadone is used for addiction treatment.
Step therapy screenout — claims reject without qualifying prior opioid fills
A claim will reject and require prior authorization if the patient has not filled at least an 8‑day supply of an IR opioid or at least a 30‑day supply of an ER opioid in the past 90 days.
- This screenout enforces the step therapy requirement to confirm prior short‑acting exposure or ER stability.
Screenout to disease‑specific benefit — cancer/SCD/palliative/hospice routed to prescription benefit
When member claims or profile indicate recent cancer, sickle cell disease, palliative care, or hospice, requests will be paid under the prescription benefit rather than this ER/LA opioid pathway.
- Disease‑specific indicators within the look‑back period (365 days) exempt the member from step therapy and post‑limit quantities described here.
Quantity limit exceedance — exceeding chart limits or '0***' strengths risks denial
Prescriptions exceeding the listed monthly or 3‑month quantity limits or strengths marked as '0***' in the Opioid Analgesics ER Quantity Limits Chart are subject to denial or non‑coverage unless prior authorization is obtained.
- Initial column limits correspond to ≤90 MME/day; post limits correspond to ≤200 MME/day with PA conditions.
PA required when no recent opioid use — absence of qualifying fills triggers PA
Claims for ER opioids will reject and require prior authorization if the patient does not have either an ≥8‑day IR opioid fill or a ≥30‑day ER opioid fill in the past 90 days.
- This enforces the step therapy requirement before allowing ER opioid dispensing without PA.
PA required for quantities above initial limits — requests > initial (~90 MME/day) require authorization
If the requested quantity exceeds the initial quantity limit (monthly quantity corresponding to ~90 MME/day), the system will reject the claim and require prior authorization to consider approval for higher dosing up to policy limits.
- Post‑approval quantities may be allowed up to ≤200 MME/day when PA criteria are met.
Coding and billing accuracy — ensure correct procedure and diagnosis codes
Use appropriate CPT, HCPCS, revenue, and/or ICD diagnostic codes to report provider services; failure to use appropriate codes may trigger billing denials.
- Accurate coding supports benefit determination and prevents billing rejections related to procedure and diagnosis reporting.
Coding, Diagnosis & MME Thresholds
| ICD-10 (unspecified list) | Diagnosis codes indicating cancer, sickle cell disease, palliative care, or hospice status used for screenout logic |
| Xtampza ER | oxycodone extended-release (covered with criteria) |
| No codes listed |
| No codes listed |
Dispensing Quantity Limits and MME Conversions
Key Definitions
Excluded Uses
Not covered under this policy are: use of long‑acting/extended‑release opioids as as‑needed (prn) analgesics; use of Xtampza ER as PRN; dispensing strengths or supply levels marked "0***" in the ER quantity limits chart unless an approved exception/authorization is obtained; and ER/LA opioid requests that fail step‑therapy or prior‑use documentation requirements. These items are explicitly identified in the policy’s exclusions and quantity‑limit rules.
Background
Long‑acting and extended‑release opioid formulations are indicated for the management of severe chronic pain requiring daily, around‑the‑clock opioid therapy when alternatives are inadequate. Due to risks of addiction, abuse, misuse, overdose, and death, these agents should be reserved for patients who have not achieved adequate pain control or tolerability with non‑opioid or immediate‑release opioid options, and they should be prescribed only by clinicians knowledgeable in potent opioid management.
Imaging Requirements
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.